Drugs & Targets FDA proposes rule aimed at ensuring safety and effectiveness of laboratory developed tests October 06, 2023Vol.49 No.37
Drugs & Targets FDA establishes pilot program to accelerate development of rare disease therapies October 06, 2023Vol.49 No.37
Drugs & Targets FDA clears automated assay to assess tumor progression in neuroendocrine cancer September 29, 2023Vol.49 No.36
Drugs & Targets Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression September 29, 2023Vol.49 No.36
Drugs & Targets Pierre Fabre Laboratories, Vernalis partner to advance cancer research September 29, 2023Vol.49 No.36
Drugs & Targets FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia September 22, 2023Vol.49 No.35
Drugs & Targets FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer September 22, 2023Vol.49 No.35
Drugs & Targets CHMP issues positive opinion on Keytruda in NSCLC indication September 22, 2023Vol.49 No.35
